US20070269465A9 - Anesthetic composition for topical administration comprising lidocaine, prilocaine and tetracaine - Google Patents

Anesthetic composition for topical administration comprising lidocaine, prilocaine and tetracaine Download PDF

Info

Publication number
US20070269465A9
US20070269465A9 US10/562,392 US56239204A US2007269465A9 US 20070269465 A9 US20070269465 A9 US 20070269465A9 US 56239204 A US56239204 A US 56239204A US 2007269465 A9 US2007269465 A9 US 2007269465A9
Authority
US
United States
Prior art keywords
pharmaceutical composition
composition according
amount
prilocaine
lidocaine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US10/562,392
Other versions
US20060140986A1 (en
US8609722B2 (en
Inventor
Fernando Fita
Original Assignee
Fita Fernando B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200301548 priority Critical
Priority to ES200301548A priority patent/ES2223277B1/en
Priority to ESP200301548 priority
Application filed by Fita Fernando B filed Critical Fita Fernando B
Priority to PCT/EP2004/050967 priority patent/WO2004110423A1/en
Publication of US20060140986A1 publication Critical patent/US20060140986A1/en
Publication of US20070269465A9 publication Critical patent/US20070269465A9/en
Application granted granted Critical
Publication of US8609722B2 publication Critical patent/US8609722B2/en
Application status is Active legal-status Critical
Adjusted expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245Amino benzoic acid types, e.g. procaine, novocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Abstract

It comprises a mixture of lidocaine, prilocaine and tetracaine, or their pharmaceutically acceptable salts. The preferred composition comprises the following components in the indicated approximate w/w percentages: 1.5% of lidocaine base; 1.5% of prilocaine base; 4% of tetracaine base; 10% of methylpynrolidone; 2% of dimethyl sulfoxide; 0.08% of topical hyaluronidase; 1.5% of guar gum; 1% of Tween-20; 0.5% of Tween-80, and the necessary amount of water to 100%. It exhibits a a high concentration on skin, a deep anesthetic effect and a significantly more rapid onset of the anesthetic effect than comparable transdermal anesthetics.

Description

  • This invention relates to the field of human medicine, and specifically to topical anesthetic formulations which include mixtures of several anesthetic agents.
  • BACKGROUND ART
  • Surgical techniques can only be performed after the highly sensitive nerve endings in the skin are anesthetized. Anesthetic agents are pharmacologically active agents that block nerve impulses conduction in sensory and motor nerve fibers when applied in therapeutically effective amounts. Their action is reversible, their use being followed by the complete recovery in nerve function with no evidence of structural damage to nerve fibers or cells.
  • To be effective, a topical anesthetic should contain sufficient concentration of the active agent to produce an anesthetic effect, it should penetrate intact skin sufficiently to deliver a therapeutic dose, it should exhibit a rapid onset of anesthetic action and have a prolonged anesthetic effect. Potency of anesthetics in clinical situations depends on both their ability to reach the nerve fibers and their intrinsic blocking activities. Factors such as nerve penetration, vascular absorption, and local tissue binding are all of them determinants for anesthetic potency.
  • Local anesthetics are traditionally injected into the desired site with a syringe. Most formulations of local anesthetics are aqueous solutions designed for injection into tissue, around nerves, or into the epidural spaces. The use of syringe is disadvantageous because the needle itself causes pain on penetration, the volume of anesthetic dissolution can cause stretching at the site (also causing pain), and furthermore preservatives contained in the aqueous dissolution can cause stinging at the wound site. Pain relief is especially important in the area of pediatrics, where even minimal pain may result in an anxious and uncooperative patient.
  • It is known the use of topical anesthetics. Transdermal delivery is advantageous over intravenous delivery because the former avoids risks associated with parenteral treatment and eliminates gastrointestinal adverse effects due to pharmaceutical active ingredients, preservatives, etc. However, the use of transdermal anesthetics (i.e. through the skin) is often problematic, and fluid and in gel compositions have often proven unsuccessful.
  • The amide of formula (I), known as lidocaine, has a melting point of 68-69° C. and it is the most commonly used local anesthetic, especially in the form of aqueous dissolutions of its hydrochloride, which are administered intravenously or topically, as jelly, ointment or spray (cf. U.S. Pat. No. 2,441,498). Unfortunately, when administered topically, these formulations are not effectively absorbed transdermally, but only through mucosal surfaces.
    Figure US20070269465A9-20071122-C00001
  • The amide of formula (II), known as prilocaine, is a local anesthetic agent which takes the form of crystalline needles having a melting point of 37-38° C. (cf. GB 839.943-A). Its hydrochloride is crystallized from ethanol and isopropyl ether and it is readily soluble in water. Unfortunately, methemoglobinaemia and cyanosis appear to occur more frequently with prilocaine than with other local anesthetics. Methemoglobinaemia is a disease state of the erythrocyte consisting in the formation of oxidized iron compound in the heme protein of the erythrocyte. Symptoms usually occur when doses of prilocaine hydrochloride exceed about 8 mg per kg body-weight although the very young may be more susceptible. This fact severely limits the size of the area to be anesthetized.
  • Enhancement of drug absorption through the skin has been a challenge for researchers for many years. Research has been also focused on finding effective topical formulations of an anesthetic which provide a rapid onset and a long duration of anesthesia. When applied onto intact skin, currently available topically used anesthetic preparations are generally ineffective or only partially effective.
  • One approach to the prolongation of anesthesia involves the combination of topical anesthetics with a vasoconstrictor, but also involves considerable adverse side effects. Another approach involves the combination of several anesthetic agents and different topical excipients (cf. e.g. EP 43.738-A, WO 9633706-A). In fact, at present, the most successful commercially available preparation for dermal anesthesia is the lidocaine-prilocaine cream named EMLA (a registered trademark in some countries) of Astra Lakemedel AB, Sweden (cf. U.S. Pat. No. 4,562,060). In some clinical tests, EMLA cream has been found preferable to lidocaine or to ethylchoride. EMLA is an oil-in-water emulsion in which the organic phase is an eutectic mixture of lidocaine and prilocaine bases (2.5% and 2.5% by weight) in water which is thickened with carbomer (Carbopol®). An eutectic mixture has a melting point lower than the one of any of its ingredients. EMLA cream is applied as a thick layer under an occlusive or semiocclusive dressing for inducing a rapid absorption through the skin.
  • A major inconvenience of EMLA is that its onset time for anesthesia is relatively long, approximately one hour or more. This onset time is not very practical for several clinical procedures. For more invasive procedures such as split skin graft harvesting, EMLA has to be applied at least two hours prior to surgical operation. Such delay is a problem for both patients and for medical staff, particularly in the area of pediatrics. Moreover, EMLA is formulated at pH 9.0 to incorporate the anesthetic agents in base form. The skin, which has an acidic pH (5 to about 5.5) is sensitive to such a high basic pH and significant skin irritation can occur. Dermal application of EMLA may cause a transient, local blanching followed by a transient, local redness or erythema. Another disadvantage of EMLA is that for deep penetrative effect it is necessary that the cream is applied under occlusive dressing.
  • There have been several attempts trying to improve EMLA cream. One example are topical anesthetic compositions which additionally include a vasodilator. A formulation including lidocaine base, prilocaine hydrochloride, dibucaine, a vasodilator and carrier is described in the patent application WO 01/54679-A. Another example is the topical anesthetic composition comprising an eutectic mixture of lidocaine and prilocaine in a lipophilic base described in the U.S. Pat. No. 5,993,836. It has been reported that this anesthetic formulation has significantly more rapid onset than similar transdermal anesthetics, such as EMLA cream.
  • Tetracaine hydrochloride (amethocaine) is a local anesthetic of the ester type with formula (III) (cf. U.S. Pat. No. 1.889.645). There are many topical formulations in the market containing tetracaine hydrochloride, one of them is AMETOP of T.J. Smith & Nephew Limited, England (cf. GB 2.258.397-A) which contains 40 mg of active ingredient (4%, w/w), an aqueous gelling agent and a pharmaceutically acceptable salt.
  • Thus, it appears to be highly desirable to have a topical anesthetic composition which provides a rapid and deep anesthesia, with a high concentration on skin. In particular, it would be desirable to have a topical anesthetic with the benefits of lidocaine and prilocaine, but free of the above-described limitations associated therewith.
  • SUMMARY OF THE INVENTION
  • It has now been surprisingly found that a topical anesthetic composition comprising a mixture of lidocaine, prilocaine and tetracaine, exhibit a significantly more rapid onset of the anesthetic effect than comparable transdermal anesthetics, such as EMLA cream.
  • Thus, an aspect of the present invention relates to a pharmaceutical composition for topical administration comprising: (i) a therapeutically safe and effective amount of lidocaine or of a pharmaceutically acceptable salt thereof; (ii) a therapeutically safe and effective amount of prilocaine or of a pharmaceutically acceptable salt thereof, and (iii) a therapeutically safe and effective amount of tetracaine or of a pharmaceutically acceptable salt thereof.
  • In a particular embodiment the composition further comprises water. When tetracaine is as its hydrochloride, it can be dissolved in water and added to the previously prepared mixture of lidocaine and prilocaine. When tetracaine is as such, water is not necessary, so tetracaine can be added to the mixture of lidocaine and prilocaine directly. Optionally, the mixture of lidocaine, prilocaine and tetracaine can also be dissolved in alcohols (e.g. ethanol, isopropanol and mixtures thereof).
  • In another embodiment, lidocaine or its salt on the one side, and prilocaine or its salt on the other side, form an eutectic mixture. As an eutectic mixture, the compositions remain liquid at room temperature and the penetration through the skin is enhanced, giving as a result, a shorter time of effect establishment, a higher efficacy and less adverse effects. Particularly, lidocaine or its salt can be in an amount from about 0.5% to about 5%, w/w, and prilocaine or its salt can be in an amount from about 0.5% to about 5%. More particularly, lidocaine, prilocaine, or their salts are in an amount of about 1.5%, w/w. On the other hand, tetracaine or its salt can be in an amount from about 0.5% to about 8%, w/w, and more particularly, in an amount of about 4%, w/w.
  • In another embodiment, the pharmaceutical composition further comprises appropriate amounts of pharmaceutically acceptable excipients to constitute a topical formulation. The composition can comprise different types of excipients: skin penetration enhancers, spreading agents, viscosity increasing agents, surfactants and preservatives. Optionally, other components can be added to the compositions of this invention in appropriate amounts to enhance their pharmaceutical acceptability, as it will be obvious to a person skilled in the art.
  • The composition can comprise at least one skin penetration enhancer which enhances dermal absorption of the active ingredients by reversibly altering the barrier of skin. Preferred skin penetration enhancer agents that may be used are dipolar aprotic solvents as methylpyrrolidone and dimethyl sulfoxide (DMSO) which are rapidly absorbed through the skin and enhance dermal absorption of many other chemicals. In a particular embodiment, methylpyrrolidone is in an amount from about 5% to about 20%, w/w. In a more particular embodiment, methylpyrrolidone is in an amount of about 10%, w/w. In another particular embodiment, the skin penetration enhancer is dimethyl sulfoxide (DMSO), which is in an amount from about 0.5% to about 5%, w/w, and more particularly in an amount of about 2%, w/w.
  • The composition can comprise at least one spreading agent, which facilitates uniform spread of anesthetic agents. In particular embodiments, the spreading agent is selected from hyalurodinases and/or derivatives of mucopolysaccharidases. They prevent the elevation of extracellular tissue pressure and also prevent focal accumulations of local anesthetic agents, which at high enough levels may cause neurotoxic damage.
  • The composition can further comprise at least one viscosity increasing agent, also known as thickening agents. Thickeners that may be used include those known to one skilled in the art, such as hydrophilic and hydroalcoholic gelling agents frequently used in cosmetics, food products and pharmaceutical formulations. Preferably, a commercial carbomer will be used, Carbopol N-940. Another preferred gelling polymer includes guar gum. In particular embodiments, the viscosity increasing agent is in an amount from about 0.5% to about 2%, w/w.
  • The composition can comprise at least one surfactant, also known as emulsifier. These compounds are widely used in the preparation of stable pharmaceutical, cosmetic and food emulsions. In a preferable embodiment the surfactant is a non-ionic surfactant and in a more particular embodiment, polysorbates are used (e.g. polysorbate 20 and 80).
  • The compositions of the present invention may be prepared and packaged under sterile conditions. Alternatively, at least one suitable antimicrobial agent may be incorporated into the formulations as preservatives. Some known preservatives useful in this invention include methylparaben and propylparaben in their acidic form or as sodium salts.
  • The topical formulations of the present invention may be made into a wide variety of product forms, as it is well known in the art. These include, among others, lotions, creams, gels, sticks, sprays, ointments and pastes. In order to facilitate the application of the compositions, they can be, for instance, in a dispenser or on the surface of a dressing, a patch or a pad. These product forms may comprise several types of carriers including, among others, dissolutions, aerosols, emulsion gels, solids and liposomes.
  • Another aspect of the present invention relates to a pharmaceutical composition for topical administration comprising the following components in the indicated approximate w/w percentages: 1.5% of lidocaine base; 1.5% of prilocaine base; 4% of tetracaine base; 10% of methylpyrrolidone; 2% of dimethyl sulfoxide; 0.08% of topical hyaluronidase; 1.5% of guar gum; 1% of Tween-20; 0.5% of Tween-80, and the necessary amount of water to 100%.
  • The application of the compositions of the present invention comprises contacting an area of skin with a thin layer of the composition. When an intravenous device is used, the application of the compositions of the present invention will be preferably at its site of insertion. The composition is allowed to act for an appropriate time for the onset of anesthesia. The term “onset of anesthesia” means the time until peak effect on the nerve endings. For the compositions of the present invention, this time is shorter than with other commercial compositions. In a preferred method of using, three consecutive applications may be done: a first application followed by ten minutes of resting to achieve the anesthetic effect; a second application followed by ten minutes more, and a third application followed by five minutes of resting. After these twenty-five minutes in all, the composition can be removed and the surgical operation can be done or the medical device can be inserted. The duration of anesthetic effect for the compositions of the present invention is from about one to about five hours, depending on the subject metabolism. The effect is much more durable and increases in time compared with other available compositions.
  • In addition to the rapid onset, the formulations of the present invention are advantageous for not depending on the application of an occlusive or a semiocclusive dressing for getting a rapid absorption through the skin. Even if it is not necessary, occlusion may be applied. The compositions of the invention may be applied directly to the skin or by the use of transdermal treatment systems, including patches or pads, which are semipermeable membranes with the active compound applied to the surface.
  • The compositions of the present invention are particularly useful before superficial dermatological treatments. These include, among others, surface verruca extirpation, infiltrations or molluscum extraction. The same applies before esthetic treatments such as peelings, filling micropuncture of wrinkles, laser or application of facial filling; and before the insertion of a medical device.
  • The term “safe and effective amount” as used herein, means an amount of an active ingredient or a composition high enough to deliver the desired skin benefit, but low enough to avoid serious side effects within the scope of medical judgment. The term “pharmaceutically acceptable” as used herein, means suitable for use in contact with the tissues without undue toxicity, irritation, incompatibility, instability, allergic response, and the like. All numerical ranges used herein, are meant to be inclusive of their upper and lower limits. Unless noted otherwise, all percentages in the compositions of the invention are on a weight-to-weight basis. Throughout the description and claims the word “comprise” is not intended to exclude other technical features, additives, components, or steps. The abstract of this application is incorporated herein as reference. Additional objects, advantages and features of the invention will become apparent to those skilled in the art upon examination of the description or may be learned by practice of the invention. The following particular embodiments are provided by way of illustration, and is not intended to be limiting of the present invention.
  • DETAILED DESCRIPTION OF PARTICULAR EMBODIMENTS
  • Preparation of the Composition
  • Tubes of 30 g were prepared with the composition per tube described in the following table:
    Component % (w/w)
    Dissolution A
    Distilled water 31.82% 
    Nipagin M-Ac 0.08%
    Nipasol M-Ac 0.02%
    Tween-20 1.00%
    Guar gum 1.50%
    Dissolution B
    Tetracaine HCl 4.00%
    Distilled water 45.00% 
    Dissolution C
    Lidocaine base  1.5%
    Prilocaine base  1.5%
    Dissolution D
    Distilled water 1.00%
    Topical hyaluronidase 0.08%
    Dissolution E
    Tween 80 0.50%
    Dissolution F
    Methylpyrrolidone   10%
    Dissolution G
    DMSO 2.00%
  • Lidocaine base and prilocaine base were weighed and sieved through a 2 mm mesh. Components of dissolutions A, B, D, E, F and G were weighed separately. The amounts of required distilled water for each dissolution were also prepared in 100 mL recipients. Distilled water for dissolution A was heated in an appropriate recipient and Nipagin and Nipasol were added until dissolved. The mixture was left to cool. Then, Tween-20 was added and the mixture was shacked with a stripping knife without lathering. Guar gum was added to the mixture and shacked during ten minutes with a glass stick. In the 100 mL recipient containing distilled water, tetracaine HCl was added and it was dissolved with a magnetic agitator during fifteen minutes at a regular speed. Tetracaine dissolution was added over dissolution A and shacked during ten minutes until homogenized. Lidocaine base was mixed with prilocaine base in a mortar during fifteen minutes until obtaining the liquefaction and consequently the total fusion of the eutectic mixture. The eutectic mixture was added over the preceding mixture and shacked during ten minutes until complete homogenization. The resulting product was transferred to a 100 mL recipient. Hyaluronidase was mixed with the corresponding amount of distilled water and shacked with a glass stick. This dissolution was added to the preceding mixture. Dissolution E, F and G were finally added consecutively and shacked until complete homogenization. The 30 g of the resulting product was transferred to an aluminum tube.
  • Comparative Clinical Study Between a Topical Anesthetic Composition of the Invention and EMLA Cream: Efficacy and Adverse Effects
  • The aim of the study was to compare the efficacy between a topical anesthetic composition of the invention versus EMLA cream. Adverse effects of both compositions were also evaluated. The study was executed during two years over a 2700 individual population with ages comprised between fifteen and sixty-five years. Different superficial dermatological procedures were made such as surface verruca extirpation, infiltrations, application of facial filling, laser or filling micropuncture of wrinkles.
  • The topical anesthetic composition of the invention was applied to the half of the population during thirty minutes previous to the surgical operation and without occlusion. EMLA was applied to the other half of the population during sixty minutes previous to the surgical operation and with occlusion. The degree of pain was evaluated by the patient himself with a visual analogous scale (VAS) with a minimum value (equivalent to no pain) “0” and a maximum value (equivalent to maximum pain) “10”. The degree of pain was evaluated during the execution of the dermatological procedure while the evaluation of adverse effects emergence was evaluated from the anesthetic application to the end of the dermatological procedure.
  • Table 1 shows the results in terms of anesthetic efficacy. Tables 2 and 3 shows the results of the evaluation of adverse effects emergence during and after the application of both creams. Table 2 shows the results in terms of adverse effects of the composition of the invention and table 3 in terms of adverse effects of EMLA. In both cases few patients with adverse effects were registered, although in the case of EMLA these effects were more acute and in the case of the composition of the invention the effects were softer, of short length and with spontaneous resolution.
    TABLE 1
    degree of pain (VAS)
    0 1 2 3 4 5 6 7 8 9 10
    EMLA 338 270 135 270 135 135 135
    the composition of 702 162 149 162 108 67
    the invention
    total patients 2700
  • TABLE 2
    adverse effects
    null soft moderate severe
    erythema 89% 10% 1% 0
    edema 99%  1% 0 0
    itching 90% 10% 0 0
  • TABLE 3
    adverse effects
    null soft moderate severe
    erythema 92.5% 0 7.5% 0
    itching 97.5% 0 2.5% 0
    cutaneous rash  100% 0 0 0
  • From the results shown in the tables, it is clear that the composition of the 10 invention proves a larger efficacy and a shorter time of effect establishment versus EMLA for the same type of dermatological and/or dermoesthetic procedure. The effectiveness of EMLA is practically the half with a double time of application.

Claims (26)

1. A pharmaceutical composition for topical administration comprising:
(i) a therapeutically safe and effective amount of lidocaine or of a pharmaceutically acceptable salt thereof;
(ii) a therapeutically safe and effective amount of prilocaine or of a pharmaceutically acceptable salt thereof; and
(iii) a therapeutically safe and effective amount of tetracaine or of a pharmaceutically acceptable salt thereof.
2. The pharmaceutical composition according to claim 1, further comprising water.
3. The pharmaceutical composition according to claim 1, wherein lidocaine or its salt on the one side, and prilocaine or its salt on the other side, form an eutectic mixture.
4. The pharmaceutical composition according to claim 3, wherein one or more of lidocaine or its salt is in an amount from about 0.5% to about 5% w/w, prilocaine or its salt is in an amount from about 0.5% to about 5% w/w, and tetracaine or its salt is in an amount from about 0.5% to about 8% w/w.
5. The pharmaceutical composition according to claim 4, wherein lidocaine or its salt is in an amount of about 1.5% w/w, and prilocaine or its salt is in an amount of about 1.5% w/w.
6. (canceled)
7. The pharmaceutical composition according to claim 4, wherein tetracaine or its salt is in an amount of about 4% w/w.
8. The pharmaceutical composition according to claim 1, further comprising appropriate amounts of pharmaceutically acceptable excipients to constitute a topical formulation.
9. The pharmaceutical composition according to claim 8, wherein the excipients comprise one or a combination of two or more of at least one skin penetration enhancer, at least one spreading agent, at least one viscosity increasing agent, at least one surfactant, and at least one preservative.
10. The pharmaceutical composition according to claim 9, wherein the skin penetration enhancer includes one or both of methylpyrrolidone and dimethyl sulfoxide (DMSO).
11. The pharmaceutical composition according to claim 10, wherein methylpyrrolidone is in an amount from about 5% to about 20% w/w.
12. The pharmaceutical composition according to claim 11, wherein methylpyrrolidone is in an amount of about 10% w/w.
13. (canceled)
14. The pharmaceutical composition according to claim 10, wherein dimethyl sulfoxide is in an amount from about 0.5% to about 5% w/w.
15. The pharmaceutical composition according to claim 14, wherein dimethyl sulfoxide is in an amount of about 2% w/w.
16. (canceled)
17. The pharmaceutical composition according to claim 9, wherein the spreading agent is selected from hyalurodinases and derivatives of mucopolysaccharidases.
18. (canceled)
19. The pharmaceutical composition according to claim 9, wherein the viscosity increasing agent is selected from guar gum and a carbomer.
20. The pharmaceutical composition according to claim 9, wherein the viscosity increasing agent is in an amount from about 0.5% to about 2% w/w.
21. (canceled)
22. The pharmaceutical composition according to claim 9, wherein the surfactant is a non-ionic surfactant.
23. (canceled)
24. The pharmaceutical composition according to claim 8, wherein the topical formulation is selected from the group consisting of lotions, creams, gels, sticks, sprays, ointments and pastes.
25. A pharmaceutical composition for topical administration comprising the following components in the indicated approximate w/w percentages: 1.5% of lidocaine base; 1.5% of prilocaine base; 4% of tetracaine base; 10% of methylpyrrolidone; 2% of dimethyl sulfoxide; 0.08% of topical hyaluronidase; 1.5% of guar gum; 1% of Tween-20; 0.5% of Tween-80, and the necessary amount of water to 100%.
26. A method of use of a combination comprising lidocaine, prilocaine and tetracaine, any of which being as such or as a pharmaceutically acceptable salt, for the preparation of a topical anesthetic pharmaceutical composition; the method comprising:
providing a combination of lidocaine, prilocaine and tetracaine themselves or as pharmaceutically acceptable salts thereof; and,
administering the combination topically.
US10/562,392 2003-06-19 2004-06-01 Anesthetic composition for topical administration comprising lidocaine, prilocaine and tetracaine Active 2028-05-30 US8609722B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES200301548 2003-06-19
ES200301548A ES2223277B1 (en) 2003-06-19 2003-06-19 Anesthetic composition for topical administration.
ESP200301548 2003-06-19
PCT/EP2004/050967 WO2004110423A1 (en) 2003-06-19 2004-06-01 Anesthetic composition for topical administration comprising lidocaine, prilocaine and tetracaine

Publications (3)

Publication Number Publication Date
US20060140986A1 US20060140986A1 (en) 2006-06-29
US20070269465A9 true US20070269465A9 (en) 2007-11-22
US8609722B2 US8609722B2 (en) 2013-12-17

Family

ID=33547868

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/562,392 Active 2028-05-30 US8609722B2 (en) 2003-06-19 2004-06-01 Anesthetic composition for topical administration comprising lidocaine, prilocaine and tetracaine

Country Status (7)

Country Link
US (1) US8609722B2 (en)
EP (1) EP2040687A1 (en)
JP (1) JP2006527734A (en)
BR (1) BRPI0411555A (en)
CA (1) CA2528360C (en)
ES (1) ES2223277B1 (en)
WO (1) WO2004110423A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011074015A2 (en) 2009-12-17 2011-06-23 Themis Medicare Limited Novel composition of pharmaceutical product to treat sexual dysfunction
US20120039960A1 (en) * 2009-04-03 2012-02-16 St. Renatus, Llc Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
US8142592B2 (en) 2008-10-02 2012-03-27 Mylan Inc. Method for making a multilayer adhesive laminate
WO2012122163A1 (en) * 2011-03-07 2012-09-13 3M Innovative Properties Company Microneedle devices and methods
WO2013101949A3 (en) * 2011-12-27 2015-06-11 JCDS Holdings, LLC Composition and method for compounded therapy
US9962391B2 (en) 2011-12-27 2018-05-08 Cmpd Licensing, Llc Composition and method for compounded therapy

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5263686B2 (en) 2006-05-16 2013-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Substituted prolinamide, use as their production and drug
KR20090082507A (en) 2006-11-20 2009-07-30 더 제너럴 하스피탈 코포레이션 Methods, compositions, and kits for treating pain and pruritis
US20080146672A1 (en) * 2006-12-08 2008-06-19 Denton Marcia Marye Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue
BRPI0704542B1 (en) * 2007-05-15 2019-07-30 Universidade Estadual De Campinas - Unicamp Pharmaceutical composition, process for obtaining pharmaceutical composition, use of a pharmaceutically efficient amount of anesthetic and geling agent, product and method of treatment
CN102112121A (en) * 2008-03-11 2011-06-29 哈佛大学校长及研究员协会 Methods, compositions, and kits for treating pain and pruritis
EP2143421A1 (en) * 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
JP5669145B2 (en) 2009-07-02 2015-02-12 国立大学法人山口大学 Surface anesthetic
US20150359767A1 (en) * 2011-12-27 2015-12-17 Cmpd Licensing, Llc Composition and method for compounded therapy
US20150359768A1 (en) * 2011-12-27 2015-12-17 Cmpd Licensing, Llc Composition and method for compounded therapy
US20150359740A1 (en) * 2011-12-27 2015-12-17 Cmpd Licensing, Llc Composition and method for compounded therapy
CN104688717A (en) * 2015-03-18 2015-06-10 华控创新(北京)药物研究院有限公司 Drug combination containing lidocaine and prilocainum
CN105769839B (en) * 2016-05-17 2019-06-11 山西远扬医药科技有限公司 A kind of compound lidocaine pharmaceutical composition and preparation method thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529601A (en) * 1977-12-01 1985-07-16 Astra Lakemedel Aktiebolag Local anesthetic mixture for topical application and method for obtaining local anesthesia
US5750139A (en) * 1994-02-18 1998-05-12 Drossapharm Ag Transdermal therapeutic system for the delivery of 5,6-benzo-alpha-pyrone
US5863941A (en) * 1995-07-06 1999-01-26 Liedtke; Rainer K. Method and composition of a topical treatment of inner ear and labyrinth symptoms
US5993836A (en) * 1998-04-28 1999-11-30 Castillo; James G. Topical anesthetic formulation
US20020006435A1 (en) * 2000-01-27 2002-01-17 Samuels Paul J. Transdermal anesthetic and vasodilator composition and methods for topical administration
US20020128285A1 (en) * 1999-10-25 2002-09-12 American Pharmed Labs, Inc. Local prevention or amelioration of pain from surgically closed wounds
US20020137813A1 (en) * 1997-02-07 2002-09-26 Queen's University At Kingston. Anaesthetic bone cement
US20030103955A1 (en) * 2000-02-21 2003-06-05 Santana Cristiano A.R. Diclofenac pharmaceutical composition based on vitamin-e, papain and hyaluronidase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1889645A (en) 1930-12-22 1932-11-29 Winthrop Chem Co Inc Beta-dimethylaminoethyl ester of para-butylamino-benzoic acid
GB9101986D0 (en) 1991-01-30 1991-03-13 Smith & Nephew Pharmaceutical compositions
SE9704031D0 (en) * 1997-11-05 1997-11-05 Astra Ab Novel formulation
US6528086B2 (en) * 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529601A (en) * 1977-12-01 1985-07-16 Astra Lakemedel Aktiebolag Local anesthetic mixture for topical application and method for obtaining local anesthesia
US5750139A (en) * 1994-02-18 1998-05-12 Drossapharm Ag Transdermal therapeutic system for the delivery of 5,6-benzo-alpha-pyrone
US5863941A (en) * 1995-07-06 1999-01-26 Liedtke; Rainer K. Method and composition of a topical treatment of inner ear and labyrinth symptoms
US20020137813A1 (en) * 1997-02-07 2002-09-26 Queen's University At Kingston. Anaesthetic bone cement
US5993836A (en) * 1998-04-28 1999-11-30 Castillo; James G. Topical anesthetic formulation
US20020128285A1 (en) * 1999-10-25 2002-09-12 American Pharmed Labs, Inc. Local prevention or amelioration of pain from surgically closed wounds
US20020006435A1 (en) * 2000-01-27 2002-01-17 Samuels Paul J. Transdermal anesthetic and vasodilator composition and methods for topical administration
US20030103955A1 (en) * 2000-02-21 2003-06-05 Santana Cristiano A.R. Diclofenac pharmaceutical composition based on vitamin-e, papain and hyaluronidase

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272656B2 (en) 2008-10-02 2019-04-30 Mylan Inc. Method for making a multilayer adhesive laminate
US8142592B2 (en) 2008-10-02 2012-03-27 Mylan Inc. Method for making a multilayer adhesive laminate
US9731490B2 (en) 2008-10-02 2017-08-15 Mylan Inc. Method for making a multilayer adhesive laminate
US9308191B2 (en) * 2009-04-03 2016-04-12 St. Renatus, Llc Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
US9855247B2 (en) 2009-04-03 2018-01-02 St. Renatus, Llc Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
US8580282B2 (en) * 2009-04-03 2013-11-12 St. Renatus, Llc Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
US20140234421A1 (en) * 2009-04-03 2014-08-21 St. Renatus, Llc Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
US20120039960A1 (en) * 2009-04-03 2012-02-16 St. Renatus, Llc Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
WO2011074015A2 (en) 2009-12-17 2011-06-23 Themis Medicare Limited Novel composition of pharmaceutical product to treat sexual dysfunction
CN103429222A (en) * 2011-03-07 2013-12-04 3M创新有限公司 Microneedle devices and methods
WO2012122163A1 (en) * 2011-03-07 2012-09-13 3M Innovative Properties Company Microneedle devices and methods
US9468599B2 (en) 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
US9724294B2 (en) 2011-12-27 2017-08-08 Cmpd Licensing, Llc Composition and method for compounded therapy
US9962391B2 (en) 2011-12-27 2018-05-08 Cmpd Licensing, Llc Composition and method for compounded therapy
WO2013101949A3 (en) * 2011-12-27 2015-06-11 JCDS Holdings, LLC Composition and method for compounded therapy

Also Published As

Publication number Publication date
JP2006527734A (en) 2006-12-07
US20060140986A1 (en) 2006-06-29
BRPI0411555A (en) 2006-08-01
CA2528360A1 (en) 2004-12-23
ES2223277A1 (en) 2005-02-16
EP2040687A1 (en) 2009-04-01
WO2004110423A1 (en) 2004-12-23
US8609722B2 (en) 2013-12-17
ES2223277B1 (en) 2006-03-01
WO2004110423A8 (en) 2006-03-02
CA2528360C (en) 2013-01-29

Similar Documents

Publication Publication Date Title
US6455066B1 (en) Intradermal-penetration agents for topical local anesthetic administration
AU694243B2 (en) Compositions for topical administration of anesthetic agents
US8128964B2 (en) Transdermal pharmaceutical delivery composition
US7157097B2 (en) Penetration enhancing and irritation reducing systems
US5093133A (en) Method for percutaneous delivery of ibuprofen using hydroalcoholic gel
CN1139380C (en) Water based externally used cream containing nitroglycerin, and prepn method and use thereof
US4863970A (en) Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
EP0672422B1 (en) Antiinflammatory and analgesic transdermal gel containing Ketoprofen
US7776349B2 (en) Organo-gel formulations for therapeutic applications
US20050276842A1 (en) Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
DE69822199T2 (en) Drugs and methods for treatment of attention disorders and attention / hyperactivity disorders with methylphenidate
JP2660839B2 (en) For topical application penetration enhancing pharmaceutical composition
USRE37727E1 (en) Method for treating nerve injury pain associated with shingles
DE60034458T2 (en) Plaster for topical use
US8652491B2 (en) Transdermal compositions for anticholinergic agents
US5807568A (en) Enhanced delivery of topical compositions containing flurbiprofen
DE60032021T2 (en) Administration of a drug using a formulation is phasenumwandelnden
US20070264317A1 (en) Imiquimod cream formulation
KR100528602B1 (en) Dermal penetration enhancer and a drug delivery system containing the same
EP0215423B1 (en) Transdermally resorbable aqueous compositions of arylpropionic-acid derivatives and process for their preparation
US5976566A (en) Non-steroidal antiinflammtory drug formulations for topical application to the skin
CA2323211C (en) Topical anesthetic formulation
US20050158348A1 (en) Vehicle for topical delivery of anti-inflammatory compounds
US8137711B2 (en) Methods of treating neuropathy
ES2330188T3 (en) pharmaceutical composition in gel or solution based dihydrotestosterone, their preparation process and their uses.

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4